Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 57Neoplasm Metastasis 21Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Brain Neoplasms 8Colorectal Neoplasms 7Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 3Recurrence 3Neoplasms 3Esophageal Neoplasms 3Adenocarcinoma 3Prostatic Neoplasms 2Meningeal Carcinomatosis 2HER2-positive Gastric Cancer 2Colonic Neoplasms 2Breast Cancer With Brain Metastasis 2Advanced Solid Tumor 2Advanced Breast Cancer 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1

Interventions

Oxaliplatin 19pembrolizumab 13Fluorouracil 12Leucovorin 11Capecitabine 11Paclitaxel 10Gemcitabine 9Docetaxel 8zolbetuximab 6cemiplimab 6Cisplatin 6Albumin-Bound Paclitaxel 6durvalumab 5Ramucirumab 5Radiotherapy 5130-nm albumin-bound paclitaxel 5Irinotecan 4Cyclophosphamide 4trastuzumab deruxtecan 3tislelizumab 3lenvatinib 3enzalutamide 3darolutamide 3Trastuzumab 3Taxes 3S 1 (combination) 3Radiosurgery 3Pemetrexed 3Nivolumab 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma × trastuzumab deruxtecan × 1 year × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Daiichi Sankyo

Phase 3 Active not recruiting
490 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡